ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,304.72
0.70%
US Tech 100
18,318.00
0.95%
다우존스 지수
39,069.59
0.01%
Bitcoin
68,700.04
0.25%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Gracell Biotechnologies Inc (GRCL)

  7. Gracell Biotechnologies Inc (GRCL) 뉴스

GRCL

Gracell Biotechnologies (GRCL)

Gracell Biotechnologies Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:GRCL
일자시간출처헤드라인심볼기업
2024/03/0502:22Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2814:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2707:28Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2707:28Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2707:26Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2707:26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2222:50Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2222:45GlobeNewswire Inc.Gracell Biotechnologies Acquisition CompletedNASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2022:22Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2024/02/2021:45GlobeNewswire Inc.Gracell Biotechnologies Announces Shareholders’ Approval of Merger AgreementNASDAQ:GRCLGracell Biotechnologies Inc
2024/02/1422:20Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:GRCLGracell Biotechnologies Inc
2024/01/3020:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2024/01/2921:00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple MyelomaNASDAQ:GRCLGracell Biotechnologies Inc
2024/01/1806:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2024/01/0906:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2024/01/0900:06PR Newswire (US)Kuehn Law Encourages KRTX, DSKE, RYZB, and GRCL Investors to Contact Law FirmNASDAQ:GRCLGracell Biotechnologies Inc
2023/12/2622:12Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2023/12/2620:44Dow Jones NewsGracell ADSs Take Flight Premarket on $1.2 Billion Takeover by AstraZenecaNASDAQ:GRCLGracell Biotechnologies Inc
2023/12/2617:05Dow Jones NewsAstraZeneca to Buy Gracell Biotechnologies for $1.2 BillionNASDAQ:GRCLGracell Biotechnologies Inc
2023/12/2616:01Business WireAstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
2023/12/2616:00GlobeNewswire Inc.Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseasesNASDAQ:GRCLGracell Biotechnologies Inc
2023/12/2220:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2023/12/2121:00GlobeNewswire Inc.Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
2023/12/1906:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRCLGracell Biotechnologies Inc
2023/12/1209:30GlobeNewswire Inc.Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023NASDAQ:GRCLGracell Biotechnologies Inc
2023/11/2920:18IH Market NewsAmazon Unveils Innovative Services, Okta Discloses Data Breach, Textron Plans 2% Global Workforce Reduction, and MoreNASDAQ:GRCLGracell Biotechnologies Inc
2023/11/2904:59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:GRCLGracell Biotechnologies Inc
2023/11/2722:00GlobeNewswire Inc.Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus ErythematosusNASDAQ:GRCLGracell Biotechnologies Inc
2023/11/2120:25Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:GRCLGracell Biotechnologies Inc
2023/11/1622:00GlobeNewswire Inc.Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease SummitNASDAQ:GRCLGracell Biotechnologies Inc
 검색 관련기사 보기:NASDAQ:GRCL

최근 히스토리

CCOM
US500
US 500
NYSE
KO
Coca Cola
AMEX
XLE
Energy Select Sector SPDR
NYSE
CVX
Chevron
COIN
ETHUSD
Ethereum
NYSE
DIS
Walt Disney
CCOM
US100
US Tech 100
AMEX
SPY
SPDR S&P 500
NYSE
NKE
Nike
NYSE
BAC
Bank of America
FX
USDGBP
US Dollar vs Sterling
USOTC
BNPQY
BNP Paribas (QX)
AMEX
XLV
Health Care Select Sector
USOTC
BASFY
BASF (QX)
PM
XAUUSD
Gold vs US Dollar
NASDAQ
NVDA
NVIDIA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유